B
Bull
Bull · 25%IRWD
$0.52
Scenario price
$3.500
-0.251 (-7.16%)At close
Loading chart…
- High
- 3.730
- Open
- 3.730
- VWAP
- 3.57
- Volume
- 2.53M
- Mkt Cap
- 985.53M
- Low
- 3.480
- Amount
- 9.04M
- EV/EBITDA, TTM
- 2.70
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
AI analysis of Ironwood Pharmaceuticals Inc (IRWD)
SellIronwood Pharmaceuticals is not a good buy right now due to significant negative trends. The stock has dropped 19.72% over the last 20 days and has an RSI of 32.098, indicating it is oversold. Additionally, insider selling has surged by 22659.51%, which raises concerns about the company's future direction and stability.
Analyst Ratings (11)
+78.00% upside
Buy
5 Buy
5 Hold
1 Sell
Current: 3.50
Low
5.00
Average
6.23
High
8.00
Citizens
Outperform
$10
2026-02-26
Citizens
2026-02-26
Price Target
$10
Outperform
Craig-Hallum
Buy
—
2026-01-05
Craig-Hallum
2026-01-05
Price Target
—
Buy
Citizens
Outperform
$8
2026-01-05
Citizens
2026-01-05
Price Target
$8
Outperform
Wells Fargo
Equal Weight
$5
2026-01-04
Wells Fargo
2026-01-04
Price Target
$5
Equal Weight
Craig-Hallum
Hold
—
2025-11-26
Craig-Hallum
2025-11-26
Price Target
—
Hold
Valuation Metrics
The current forward P/E ratio for Ironwood Pharmaceuticals Inc (IRWD) is 12.33, compared to its 5-year average forward P/E of 14.77.
Alphio AI Price Scenarios for IRWD
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding IRWD
Events Timeline
News
5.010-16NewsfilterIronwood CEO McCourt Retires, Gaskins Appointed Successor
2.008-13NASDAQ.COMIronwood (IRWD) Q2 2026 Earnings Call Transcript
5.007-14NASDAQ.COMIronwood Pharmaceuticals Appoints New CMO
8.505-29NASDAQ.COMRegulatory Approvals and Collaborations in Biotech Sector
9.005-28NASDAQ.COMFDA Approves LINZESS for Pediatric Functional Constipation Treatment
IRWD FAQ — answered by Alphio AI
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Ironwood Pharmaceuticals is not a good buy right now due to significant negative trends. The stock has dropped 19.72% over the last 20 days and has an RSI of 32.098, indicating it is oversold. Additionally, insider selling has surged by 22659.51%, which raises concerns about the company's future direction and stability.
11 analysts cover IRWD: 5 rate it Buy, 5 Hold and 1 Sell. The average price target is 6.23.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.